ASAP1, a gene at 8q24, is associated with prostate cancer metastasis

Cancer Research

Volumn 68, Issue 11, 2008, Pages 4352-4359

  Lin, Dong ^a   Watahiki, Akira ^a   Bayani, Jane ^c   Zhang, Fang ^a   Liu, Lin ^a   Ling, Victor ^a   Sadar, Marianne D ^a   English, John ^b   Fazli, Ladan ^b   So, Alan ^b   Gout, Peter W ^a   Gleave, Martin ^b   Squire, Jeremy A ^c   Wang, Yu Zhuo ^a,b,d  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; SMALL INTERFERING RNA; DDEF1 PROTEIN, HUMAN; PRIMER DNA; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASAP1 GENE; CANCER CELL; CELL MIGRATION; CONTROLLED STUDY; CYTOPLASM; DRUG SCREENING; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SCID MOUSE; SERIAL ANALYSIS OF GENE EXPRESSION; UPREGULATION; XENOGRAFT; ANIMAL; CELL FRACTIONATION; CHROMOSOME 8; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 8; DNA PRIMERS; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; SUBCELLULAR FRACTIONS;

EID: 49249106186     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-5237     Document Type: Article

References (39)

1. Isaacs JT. New strategies for the medical treatment of prostate cancer. BJU Int 2005;96 Suppl 2:35-40.
2. Foley R, Hollywood D, Lawler M. Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease. Endocr Relat Cancer 2004;11:477-88.
3. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004;113:913-23.
4. Fidler IJ. The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revisited. Nat Rev Cancer 2003;3:453-8.
5. Varambally S, Yu J, Laxman B, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005;8:393-406.
6. Paris PL, Weinberg V, Simko J, et al. Preliminary evaluation of prostate cancer metastatic risk biomarkers. Int J Biol Markers 2005;20:141-5.
7. Gutman S, Kessler LG. The U.S. Food and Drug Administration perspective on cancer biomarker development. Nat Rev Cancer 2006;6:565-71.
8. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003;9:4227-39.
9. Sharpless NE, Depinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 2006;5:741-54.
10. Fidler IJ. Critical determinants of metastasis. Semin Cancer Biol 2002;12:89-96.
11. Wang Y, Xue H, Cutz JC, et al. An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab Invest 2005;85:1392-404.
12. Wang Y, Revelo MP, Sudilovsky D, et al. Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate 2005;64:149-59.
13. Saha S, Sparks AB, Rago C, et al. Using the transcriptome to annotate the genome. Nat Biotechnol 2002;20:508-12.
14. Onodera Y, Hashimoto S, Hashimoto A, et al. Expression of AMAP1, an ArfGAP, provides novel targets to inhibit breast cancer invasive activities. EMBO J 2005;24:963-73.
15. Ohl F, Jung M, Xu C, et al. Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization? J Mol Med 2005;83:1014-24.
16. Lee CH, Xue H, Sutcliffe M, et al. Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol Oncol 2005;96:48-55.
17. Cutz JC, Guan J, Bayani J, et al. Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes. Clin Cancer Res 2006;12:4043-54.
18. Todaro GJ, Lazar GK, Green H. The initiation of cell division in a contact-inhibited mammalian cell line. J Cell Physiol 1965;66:325-33.
19. Hendrix MJ, Seftor EA, Seftor RE, Fidler IJ. A simple quantitative assay for studying the invasive potential of high and low human metastatic variants. Cancer Lett 1987;38:137-47.
20. Gao AC, Lou W, Dong JT, Isaacs JT. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res 1997;57:846-9.
21. Bussemakers MJ, van Moorselaar RJ, Giroldi LA, et al. Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res 1992;52:2916-22.
22. Umbas R, Schalken JA, Aalders TW, et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992;52:5104-9.
23. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4pathway in prostate cancer metastasis to bone. Cancer Res 2002;62:1832-7.
24. Thompson TC. Metastasis-related genes in prostate cancer: the role of caveolin-1. Cancer Metastasis Rev 1998;17:439-42.
25. Zhau HE, Pisters LL, Hall MC, et al. Biomarkers associated with prostate cancer progression. J Cell Biochem Suppl 1994;19:208-16.
26. Kibel AS, Freije D, Isaacs WB, Bova GS. Deletion mapping at 12p12-13 in metastatic prostate cancer. Genes Chromosomes Cancer 1999;25:270-6.
27. Hoosein NM, Boyd DD, Hollas WJ, Mazar A, Henkin J, Chung LW. Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines. Cancer Commun 1991;3:255-64.
28. Xu J, Wang R, Xie ZH, et al. Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate 2006;66:1664-73.
29. Randazzo PA, Hirsch DS. Arf GAPs: multifunctional proteins that regulate membrane traffic and actin remodelling. Cell Signal 2004;16:401-13.
30. Ehlers JP, Worley L, Onken MD, Harbour JW. DDEF1 is located in an amplified region of chromosome 8q and is overexpressed in uveal melanoma. Clin Cancer Res 2005;11:3609-13.
31. Visakorpi T, Kallioniemi AH, Syvanen AC, et al. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 1995;55:342-7.
32. Yeager M, Orr N, Hayes RB, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007;39:645-9.
33. Haiman CA, Patterson N, Freedman ML, et al. Multiple regions within 8q24independently affect risk for prostate cancer. Nat Genet 2007;39:638-44.
34. Gudmundsson J, Sulem P, Manolescu A, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007;39:631-7.
35. Kim JH, Dhanasekaran SM, Mehra R, et al. Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res 2007;67:8229-39.
36. Tsuchiya N, Kondo Y, Takahashi A, et al. Mapping and gene expression profile of the minimally overrepresented 8q24region in prostate cancer. Am J Pathol 2002;160:1799-806.
37. Porkka KP, Tammela TL, Vessella RL, Visakorpi T. RAD21 and KIAA0196 at 8q24are amplified and overexpressed in prostate cancer. Genes Chromosomes Cancer 2004;39:1-10.
38. van Dekken H, Alers JC, Damen IA, et al. Genetic evaluation of localized prostate cancer in a cohort of forty patients: gain of distal 8q discriminates between progressors and nonprogressors. Lab Invest 2003;83:789-96.
39. Ribeiro FR, Jeronimo C, Henrique R, et al. 8q gain is an independent predictor of poor survival in diagnostic needle biopsies from prostate cancer suspects. Clin Cancer Res 2006;12:3961-70.